Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Inclusion Criteria: * Diagnosis of congenital hemophilia A or B with inhibitors * Male or Female, age 12 or older * History of frequent bleeding episodes * Affirmation of informed consent with signature confirmation and assent for children between ages 12 to 17 before any study related activities Exclusion Criteria: * Previous participation in a clinical trial evaluating a modified rFVIIa agent * Received an investigational drug within 30 days or 5 half-lives or absence of clinical effect * Known hypersensitivity to trial or related product * Known positive antibody to FVII or FVIIa detected by central lab at screening * Have a coagulation disorder other than hemophilia A or B * Be immunosuppressed * Significant contraindication to participate